August 2026—Pictor Holdings debuted its next-generation high-resolution platform, the PictImager, at the Association for Diagnostics and Laboratory Medicine Annual Meeting and Clinical Lab Expo (July 26–30, Anaheim, Calif.). Designed to support scalable targeted protein analysis in research laboratories, the platform integrates Pictor’s PictArray, PictImager, and Pictorial software into a streamlined workflow built around standard 96-well laboratory formats.
The PictImager builds on earlier Pictor imaging systems that were developed primarily for research and technology development; the updated instrument incorporates enhanced design for improved usability and imaging capability and a more robust architecture intended to support beta-site evaluation and broader commercial deployment. The imager reads a 96-well plate in less than one minute, and the platform supports multiple sample types, including serum, plasma, saliva, cerebrospinal fluid, and nasal swabs. It is for research use only.
In a separate release, the company announced a collaboration with BioAffinity Technologies to develop next-generation diagnostic tests for asthma and chronic obstructive pulmonary disease, combining BioAffinity’s flow cytometry expertise with Pictor’s targeted proteomic platform.
Pictor, 800-641-1096